Ligand Pharmaceuticals (LGND) P/E Ratio
P/E Ratio as of Jul 2, 2025: -15.97
Average-15.76
Median-15.97
Minimum-16.61
Maximum-14.38
-15.97
Past Month-1.69 (11.83%)
The P/E ratio for Ligand Pharmaceuticals (LGND) is -15.97 as of Jul 2, 2025. This represents a decrease of -89.53% compared to its 12-month average P/E ratio of -152.51. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Ligand Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Ligand Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Ligand Pharmaceuticals to industry peers.
Ligand Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Ligand Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Ligand Pharmaceuticals to industry peers.
Ligand Pharmaceuticals (LGND) P/E Ratio Insights
See Ligand Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares
Ligand Pharmaceuticals (LGND) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jul 1, 2025 | $112.56 | -15.81 |
| Jun 2, 2025 | $101.64 | -14.28 |
| May 1, 2025 | $109.15 | -708.77 |
| Apr 1, 2025 | $104.82 | -680.65 |
| Mar 3, 2025 | $112.18 | -728.44 |
| Feb 3, 2025 | $114.76 | 45.66 |
| Jan 2, 2025 | $108.42 | 43.14 |
Ligand Pharmaceuticals (LGND) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -15.97 | -137.46% |
| 2024 | 42.63 | -50.06% |
| 2023 | 85.36 | -258.54% |
| 2022 | -53.84 | -291.06% |
| 2021 | 28.18 | -109.68% |
| 2020 | -291.17 | — |
FAQs About Ligand Pharmaceuticals (LGND) P/E ratio
The latest P/E ratio of Ligand Pharmaceuticals (LGND) is -15.97, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Ligand Pharmaceuticals’s last 12-month average P/E ratio is -152.51, compared to its current P/E ratio of -15.97. This reflects a decrease of -89.53%.
Ligand Pharmaceuticals’s current P/E ratio of -15.97 is lower than its last 12-month average P/E of -152.51. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Ligand Pharmaceuticals’s average P/E ratio over the last 3 years is -45.59. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Ligand Pharmaceuticals’s average P/E ratio over the last 5 years is -47.37. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.